WallStreetZenWallStreetZen

NASDAQ: TNGX
Tango Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

TNGX past revenue growth

How has TNGX's revenue growth performed historically?
Company
46.93%
Industry
151.46%
Market
17.61%
TNGX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TNGX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TNGX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TNGX earnings and revenue history

Current Revenue
$36.5M
Current Earnings
-$101.7M
Current Profit Margin
-278.5%

TNGX Return on Equity

Current Company
-42%
Current Industry
-63.5%
Current Market
188%
TNGX's Return on Equity (-42%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when TNGX announces earnings.

TNGX Return on Assets

Current Company
-25.2%
Current Industry
2.9%
TNGX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

TNGX Return on Capital Employed

Current Company
-28.49%
Current Industry
19.5%
TNGX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TNGX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
TNGX$36.53M-$95.59M-$101.74M+10.33%N/A
ALXO$0.00-$158.40M-$160.81M-100.00%N/A
SAGE$86.46M-$540.10M-$541.49M-0.86%N/A
CGEM$0.00-$166.97M-$153.16M-100.00%N/A
RLAY$25.55M-$336.70M-$341.97M-88.41%N/A
View Top Biotech Stocks

TNGX earnings dates

Next earnings date
May 7, 2024

Tango Therapeutics Earnings & Revenue FAQ

What were TNGX's earnings last quarter?

On Invalid Date, Tango Therapeutics (NASDAQ: TNGX) reported Q4 2023 earnings per share (EPS) of -$0.30, up 9.09% year over year. Total Tango Therapeutics earnings for the quarter were -$30.76 million. In the same quarter last year, Tango Therapeutics's earnings per share (EPS) was -$0.33.

If you're new to stock investing, here's how to buy Tango Therapeutics stock.

What was TNGX's earnings growth in the past year?

As of Q2 2024, Tango Therapeutics's earnings has grown year over year. Tango Therapeutics's earnings in the past year totalled -$101.74 million.

What is TNGX's earnings date?

Tango Therapeutics's earnings date is Invalid Date. Add TNGX to your watchlist to be reminded of TNGX's next earnings announcement.

What was TNGX's revenue last quarter?

On Invalid Date, Tango Therapeutics (NASDAQ: TNGX) reported Q4 2023 revenue of $5.43 million up 15.29% year over year. In the same quarter last year, Tango Therapeutics's revenue was $6.41 million.

What was TNGX's revenue growth in the past year?

As of Q2 2024, Tango Therapeutics's revenue has grown 46.93% year over year. This is 104.53 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Tango Therapeutics's revenue in the past year totalled $36.53 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.